Ferring's New Chief Falk Talks
Executive Summary
Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.
You may also be interested in...
Ferring Plots Genomics Path With Celmatix Pact
The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.
Ferring Makes Foray Into Gene Therapy With FKD Pact
The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.
Interview: Ferring Forges Ahead With mAbs For Reproductive Meds
Antibody-based therapies have not really been investigated in the area of reproductive medicine and women’s health but Ferring is investing heavily to explore their potential, head of global pharmaceutical R&D Armin Metzger tells Scrip.